Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

This study has been terminated.
(Administratively complete.)
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: February 5, 2003
Last updated: April 8, 2013
Last verified: April 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)